



FOR IMMEDIATE RELEASE

News Release

4 February, 2025

PreveCeutical Announces Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects

Vancouver, British Columbia: (4 February, 2025) - PreveCeutical Medical Inc. (CSE: PREV, OTCQB: PRVCF, FSE: 18H), (the “Company” or “PreveCeutical”) a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products is pleased to announce that it has appointed Dr. Bryan Jones (“Bryan”) as an advisor to the Company as Director of Sol-Gel Special Projects effective 31 January, 2025.

Bryan Jones brings over 30 years of drug development experience from both a scientific and business development aspect. He is currently the Chief Operating Officer of Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Prior to joining Aardvark, he was Co-Founder of Sollis Therapeutics Inc. and served as its Chief Operating Officer from May 2017 to May 2020, where he led technology transfer, manufacturing of a drug/device combination, and execution of the company’s Phase 3 Sciatica program. He was also a Co-founder of Sherrington Pharmaceuticals which was sold to Sorrento Therapeutics in 2013.

He started his career in the laboratory at Bristol-Myers Squibb Company and on products such as Cialis® with ICOS and has held progressively higher positions in Business Development, Operations and C-Suite roles during the course of his career.

Dr. Jones received his Ph.D. in Genetics from the University of Washington and a bachelor’s degree in biology and Biochemistry from Iowa State University.

Stephen Van Deventer, CEO of PreveCeutical, commented:

“Having Bryan join our team to advance Sol-Gel to deliver Nose to Brain delivery of different therapeutics to prevent or manage symptoms caused by disease and other ailments, will allow us to accelerate this program rapidly. In the near term we will provide further details on our first targeted therapeutic. Bryan’s expertise and experience will be a great asset to PreveCeutical.”

Bryan Jones remarked on his appointment:

“The science developed at PreveCeutical has the potential to increase the therapeutic window and result in much safer treatment options for patients. I am excited to work with the team to advance this innovative technology into as many different therapeutic options as feasible.”

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on [Twitter](#) and [Facebook](#).

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical’s anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical’s research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the

financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.